Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Oxymorphone Immediate-Release Study Cleared By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency grants final approval to short-term, repeat-dose study of oxymorphone IR. FDA asks Endo to clarify aspects of its outcomes analysis for a new trial of an extended-release formulation prior to final approval of study protocol.

You may also be interested in...



Endo Oxymorphone ER Protocol Approved

Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.

Endo Oxymorphone ER Protocol Approved

Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.

Endo Oxymorphone ER Response To FDA “Approvable” Letter Expected In 2005

The firm will submit a new study, designed under FDA’s special protocol assessment procedures, in 250-300 opioid-naïve patients with chronic low back pain. Bias concerns raised about dropouts in other trials will be addressed through titration.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel